Anti-tumor effect of boron neutron capture therapy in pelvic human colorectal cancer in a mouse model - 10/09/22
Abstract |
Local recurrence of colorectal cancer (CRC) can occur in patients after curative resection, and additional surgical resection may therefore be required; however, this is a significant burden for patients, because additional surgical resection may necessitate the resection of other organs such as the bladder, prostate, uterus, or sacral bone. Therefore, there is a need for alternative therapeutic strategies. We focused on boron neutron capture therapy (BNCT) as a treatment modality that can selectively target tumor cells without excessive damage to normal tissues. The usefulness of BNCT to pelvic CRC remains unknown. This study investigated the anti-cancer effect of boronophenylalanine (BPA)-mediated BNCT in a previously established mouse model of pelvic recurrence of CRC. Uptake of BPA in CRC was observed both in vitro and in vivo, and the concentrations were sufficient for BNCT. Our results are the first to show that BPA-mediated BNCT prolonged the survival of experimental mice with pelvic tumors; moreover, it did not cause any obvious severe side effects in the treated animals. In conclusion, BPA-mediated BNCT could contribute to treating local recurrence of pelvic CRC.
Le texte complet de cet article est disponible en PDF.Highlights |
• | BPA uptake sufficient for BNCT was observed in CRC both in vitro and in vivo. |
• | BPA-mediated BNCT had anti-cancer effects in a pelvic CRC mouse model. |
• | No side effects of BPA-mediated BNCT were observed in pelvic organs. |
Abbreviations : BPA, BNCT, CRC, CT, ICP-AES, LET, HE, T/B, T/N, FBS, PBS, SEM
Keywords : Boron neutron capture therapy, Colorectal cancer, Pelvic recurrence, Boronophenylalanine
Plan
Vol 154
Article 113632- octobre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?